183 related articles for article (PubMed ID: 18047674)
1. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.
Wang XD; Reeves K; Luo FR; Xu LA; Lee F; Clark E; Huang F
Genome Biol; 2007; 8(11):R255. PubMed ID: 18047674
[TBL] [Abstract][Full Text] [Related]
2. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.
Huang F; Reeves K; Han X; Fairchild C; Platero S; Wong TW; Lee F; Shaw P; Clark E
Cancer Res; 2007 Mar; 67(5):2226-38. PubMed ID: 17332353
[TBL] [Abstract][Full Text] [Related]
3. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy.
Moulder S; Yan K; Huang F; Hess KR; Liedtke C; Lin F; Hatzis C; Hortobagyi GN; Symmans WF; Pusztai L
Mol Cancer Ther; 2010 May; 9(5):1120-7. PubMed ID: 20423993
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Yu EY; Wilding G; Posadas E; Gross M; Culine S; Massard C; Morris MJ; Hudes G; Calabrò F; Cheng S; Trudel GC; Paliwal P; Sternberg CN
Clin Cancer Res; 2009 Dec; 15(23):7421-8. PubMed ID: 19920114
[TBL] [Abstract][Full Text] [Related]
6. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: BMS 354825.
Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
10. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Jabbour E; Cortes J; Kantarjian H
Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Taylor MJ; Scuffham PA
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
[TBL] [Abstract][Full Text] [Related]
14. Initial testing of dasatinib by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock RB; Tajbakhsh M; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2008 Jun; 50(6):1198-206. PubMed ID: 17914733
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Santos FP; Cortes J
Expert Opin Pharmacother; 2012 Nov; 13(16):2381-95. PubMed ID: 22992064
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Verstovsek S; Tefferi A; Cortes J; O'Brien S; Garcia-Manero G; Pardanani A; Akin C; Faderl S; Manshouri T; Thomas D; Kantarjian H
Clin Cancer Res; 2008 Jun; 14(12):3906-15. PubMed ID: 18559612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
